Traws Pharma advances antiviral pipeline with multiple regulatory submissions

1 week ago 1

Healthcare

Traws Pharma (NASDAQ:TRAW) on Monday announced multiple regulatory submissions related to its antiviral pipeline.
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere.
Briefing documents submitted to

Recommended For You

More Trending News

Read Entire Article